Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | CTSV | O60911 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205393 | 0.84 | CRHBP (0.70) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL4214475 | 0.84 | CRHBP (0.70) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL9834480 | 0.84 | CRHBP (0.70) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL17434401 | 0.79 | MAPT (0.70) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL4897621 | 0.79 | KDM4E (0.57) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL9835626 | 0.79 | MAPT (0.68) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL5265055 | 0.78 | MAPT (0.64) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL3462629 | 0.78 | MAPT (0.64) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL4208131 | 0.78 | MAPT (0.60) | MAPTCTSVCTSLKMT2AMEN1 | |
| SCHEMBL9833089 | 0.77 | MAPT (0.70) | MAPTCTSVCTSLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | claimed |
| US-8372808-B2 | Suppression of glial fibrillary acidic protein | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-02-12 | — | — | US | claimed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-4159213-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN PREVENTION AND/OR TREATMENT AND/OR CURE OF HEPATITIS B VIRUS | Katholieke Universiteit Leuven (BE) | 2023-04-05 | — | — | EP | disclosed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200197544-A1 | JCV IMAGING METHODS AND COMPOSITIONS | BIOGEN MA INC (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3615681-A1 | JCV IMAGING METHODS AND COMPOSITIONS | Biogen MA Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3025714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9233107-B2 | Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) | BIOGEN MA INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-8871463-B2 | Method for screening a glutamate release inhibitor in an astrocyte | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-10-28 | — | — | US | disclosed |
| WO-2013123403-A1 | THERANOSTICS PLATFORM AND METHODS OF USE | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MAPT 357/4885CTSV 3238/4885CTSL 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.